Combined analysis of SUSTAIN 6 and PIONEER 6 showed semaglutide reduced MACE by 24% and stroke by 35% versus placebo in type 2 diabetes.
35% stroke reductionsemaglutide vs placebo in 6,480 type 2 diabetes patients from SUSTAIN 6 + PIONEER 6
What the researchers found
Combining individual patient-level data from SUSTAIN 6 (injectable semaglutide) and PIONEER 6 (oral semaglutide) versus placebo:
Overall MACE: HR 0.76 (95% CI 0.62-0.92), a 24% reduction. This was statistically significant.
Individual components: non-fatal stroke showed the strongest effect at HR 0.65 (95% CI 0.43-0.97), a 35% reduction. CV death and non-fatal MI showed numerical reductions but individual confidence intervals were wider.
Heart failure hospitalization: HR 1.03 (95% CI 0.75-1.40), no benefit. Notably, patients with prior heart failure also showed no MACE benefit (interaction P = 0.046).
Subgroup analyses: consistent MACE reduction in patients with and without established CV disease or chronic kidney disease, and in patients with and without prior MI or stroke (all interaction P > 0.05 except HF).
In the combined glycemic efficacy trials (where comparators included active drugs, not just placebo), MACE HR was 0.85 (95% CI 0.55-1.33).
Why it matters
This pooled analysis provides the strongest cardiovascular evidence for semaglutide from its dedicated outcome trials. The 24% MACE reduction and particularly the 35% stroke reduction support semaglutide as a cardiovascular protective drug, not just a glucose-lowering agent. The lack of heart failure benefit is clinically important for patient selection.
The numbers in context
MACE HR 0.76 (0.62-0.92); stroke HR 0.65 (0.43-0.97); HF HR 1.03 (no benefit); consistent across subgroups except prior HF
How the study worked
Pre-specified post hoc analysis combining individual patient-level data from two cardiovascular outcome trials: SUSTAIN 6 (n=3,297) and PIONEER 6 (n=3,183). Cox proportional hazards models for time-to-first MACE and components. Subgroup analyses by baseline CV risk factors.
Who was studied
~6,480 type 2 diabetes patients from SUSTAIN 6 and PIONEER 6 cardiovascular outcome trials
What this study cannot tell us
Post hoc combined analysis. The two trials had different designs (SUSTAIN 6 was longer). Subgroup analyses, while consistent, have reduced statistical power. The heart failure null finding is based on a relatively small number of events. The glycemic efficacy trial analysis was underpowered for CV endpoints.
How to read the evidence
Strong evidence from pooled individual patient-level data of two cardiovascular outcome trials (n=6,480), though as a post hoc analysis the findings are supportive rather than definitive.
When this study was published
Published in 2020. The SELECT trial has since confirmed cardiovascular benefits in non-diabetic obesity, broadening the evidence base.
The bigger picture
This is the definitive cardiovascular dataset for semaglutide from its dedicated outcome trials. The 35% stroke reduction is particularly noteworthy and has supported semaglutide's positioning as a cardiovascular protective drug, not just a diabetes medication.
Questions still open
- Why did patients with prior heart failure not benefit?
- Is the stroke reduction mechanism specific to semaglutide or shared by all GLP-1 drugs?
- Will the SELECT trial confirm similar benefits in non-diabetic patients?
Common questions
What does a 35% stroke reduction mean practically?
Why didn't semaglutide help with heart failure?
Read the original research
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
Diabetes, obesity & metabolism, 22(3), 442-451
Citation
Husain, Mansoor; Bain, Stephen C; Jeppesen, Ole K; Lingvay, Ildiko; Sørrig, Rasmus; Treppendahl, Marianne B; Vilsbøll, Tina. (2020). Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.. Diabetes, obesity & metabolism, 22(3), 442-451. https://doi.org/10.1111/dom.13955